Research Analysts Offer Predictions for BRTX Q1 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Research analysts at Roth Capital issued their Q1 2025 earnings estimates for BioRestorative Therapies in a report released on Tuesday, November 5th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings of ($0.34) per share for the quarter. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.83) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.27) EPS, FY2027 earnings at $2.47 EPS and FY2028 earnings at $5.43 EPS.

BioRestorative Therapies (NASDAQ:BRTX) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.06. The firm had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative return on equity of 107.65% and a negative net margin of 6,898.28%. During the same period in the previous year, the firm posted ($0.77) EPS.

Separately, Roth Mkm raised their price target on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, August 14th.

BioRestorative Therapies Trading Up 6.5 %

Shares of NASDAQ:BRTX opened at $1.65 on Wednesday. The stock has a fifty day simple moving average of $1.63 and a two-hundred day simple moving average of $1.58. BioRestorative Therapies has a 12-month low of $1.03 and a 12-month high of $3.67. The stock has a market capitalization of $11.42 million, a price-to-earnings ratio of -0.81 and a beta of 63.40.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.